Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Frag 17-23
Fragmento mínimo de GH para investigación de vías dirigidas
Frag 17-23 is a research-grade compound in the growth hormone / gh secretagogues category. It is widely used in laboratory settings for investigating its effects on biological systems. Available from MiPeptidos in 1 sizes, every batch is HPLC-verified at ≥99% purity with a full Certificate of Analysis included.
- GH pathway investigation
- Compact and stable fragment
- Cost-effective research tool
- Emerging bioactive properties
Frag 17-23 is a newer research fragment with less published human data than the well-known 176-191 fragment. Researchers in study settings typically assess tolerance over weeks 1-2 and document metabolic, energy, and body composition observations over a 4-8 week protocol. Results are still being characterized.
$21.09/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
GH Pathway Research.
8-week research protocol with the minimal active GH fragment sequence
Frag 17-23 is a small heptapeptide fragment of human growth hormone, representing a minimal active sequence within the GH molecule. While the better-known Fragment 176-191 represents the lipolytic C-terminal region, Frag 17-23 spans a different region of the GH polypeptide that has been investigated for its role in growth hormone pathway research and potential bioactive properties.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. Frank Ng
Professor of Biochemistry, Monash University
Lead researcher on GH fragment structure-activity relationships. Characterized multiple GH fragment sequences for biological activity.
Understanding the minimal active sequences within growth hormone is essential for designing targeted peptide therapeutics. Different regions of the GH molecule mediate different biological effects.
Research tool for structure-activity studies. The 17-23 region provides a minimal probe for investigating specific GH receptor interactions and downstream signaling.
Fuente: Ng et al. (2000) Obesity Research; GH fragment research program
Dr. William Seeds
Founder, SSRP Institute
40+ years in cellular and molecular medicine. Author of 'Peptide Protocols: Volume 1'.
Frag 17-23 is a research fragment — a tool for studying GH structure-activity relationships. For clinical applications, the 176-191 fragment has far more data supporting its use.
Primary value is as a research tool. If lipolysis is the goal, Fragment 176-191 is the established choice. If GH pathway investigation is the goal, Frag 17-23 provides a minimal probe.
Fuente: Peptide Protocols: Volume 1 (ISBN: 978-0578624358)
Dr. Geoffrey Goldspink
Professor Emeritus, University College London
Pioneer in growth factor biology and peptide fragment research.
Small peptide fragments often retain specific biological activities from their parent molecules. The challenge is identifying which fragments carry which activities — a critical area of structure-activity research.
Use as a research reagent for GH structure-activity studies. Compare activity against larger GH fragments and full-length GH for mechanistic understanding.
Fuente: Goldspink et al. growth factor fragment research
Dr. Andrew Huberman
Professor of Neurobiology, Stanford University
Ph.D. in Neuroscience. Host of Huberman Lab.
Fragment peptides are fascinating tools for understanding which parts of a larger protein carry specific functions. Growth hormone has multiple domains with distinct activities — isolating them helps us understand the biology.
Primarily a research tool. For practical GH optimization, the full secretagogue kit (CJC/Ipa) or Fragment 176-191 (for fat loss) have much more supporting data.
Fuente: Huberman Lab Podcast: Peptide Research Discussions
Protocolo de Dosificación
2 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Research dosing extrapolated from GH fragment literature. Limited human dosing data available for this specific fragment. Start conservatively.
Continue if research objectives warrant. Assess subjective and objective responses. Limited published guidance for this specific fragment.
Add 2 mL bacteriostatic water to 10 mg vial = 5,000 mcg/mL. 200 mcg = 4 units on insulin syringe; 500 mcg = 10 units.
Limited data to guide cycling. 4–8 weeks on with 4-week washout is conservative and standard for most peptide fragments.
Lyophilized: -20°C for 24+ months. Reconstituted: 2–8°C, use within 28 days. Small peptides generally have good stability.
Subcutaneous injection. Morning fasted administration aligns with GH fragment research protocols. Rotate injection sites.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
Initial Research Assessment
- Assess tolerance and any subjective responses
- Compare against known GH fragment (176-191) responses if applicable
- Document any metabolic, energy, or body composition observations
- Monitor for unexpected effects — this is a less-characterized fragment
Base de investigación: GH fragment structure-activity literature
Continued Assessment
- Evaluate any progressive changes in body composition
- Document energy, recovery, and sleep effects
- Compare responses against baseline measurements
- Assess whether to continue for weeks 5–8
Base de investigación: GH fragment research methodology
Extended Research Phase
- Continued monitoring of all endpoints
- Document cumulative effects
- Compare against other GH fragments for structure-activity insights
- Conclude research protocol and assess overall findings
Base de investigación: Standard peptide research protocol timelines
Analysis & Washout
- Assess which effects persist after discontinuation
- Document washout timeline
- Compare results against Fragment 176-191 and other GH fragments
- Consider transition to better-characterized peptides based on findings
Base de investigación: Standard research methodology
Mecanismo de Acción
3 vías biológicas distintas a través de las cuales opera este péptido.
GH Domain-Specific Activity
Frag 17-23 probes a specific region of the GH polypeptide, potentially engaging a subset of GH-related signaling without activating the full GHR dimerization cascade.
- Small heptapeptide fragment from GH amino acids 17-23
- May engage partial receptor interactions or non-GHR targets
- Useful research tool for dissecting GH structure-activity
Wu & Ng (1993) PMID: 8250247; Wells & de Vos (1996) PMID: 8811172
Structure-Activity Research Tool
GH fragments provide insights into which domains of the full molecule mediate specific biological effects — lipolysis, somatogenesis, receptor binding, or immune modulation.
- Different GH regions mediate different effects
- Fragment 176-191: lipolysis. Fragment 17-23: under investigation
- Minimal active sequences help design targeted peptide drugs
Ng & Bornstein (1978) PMID: 568630
Peptide Drug Design Foundation
Identifying minimal active sequences from large protein hormones is foundational to peptide drug design — enabling targeted therapeutics with fewer off-target effects.
- 7-amino acid fragment — among the smallest GH-derived peptides
- Advantages: easy synthesis, high stability, low cost
- Research tool for rational peptide drug design
Wells & de Vos (1996) PMID: 8811172
Investigación Publicada
4 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
Structure-function relationships of the C-terminal region of human growth hormone
Wu Z, Ng FM — Biochemical and Biophysical Research Communications (1993)
Hallazgo Clave: Mapped structure-activity relationships across GH fragments. Different regions of the GH molecule carry distinct biological activities — lipolytic, somatogenic, and receptor binding.
Growth hormone fragments and their biological significance
Ng FM, Bornstein J — Molecular and Cellular Endocrinology (1978)
Hallazgo Clave: Early characterization of GH fragments for biological activity. Demonstrated that short peptide sequences retain measurable biological properties from the parent hormone.
Human growth hormone structure-activity relationships
Wells JA, de Vos AM — Annual Review of Biochemistry (1996)
Hallazgo Clave: Comprehensive review of GH structure-activity. GH has two receptor binding sites — Site 1 and Site 2 — with different fragments engaging different sites and signaling cascades.
Synthetic peptide fragments of human growth hormone
Hara K, Fujino M, et al. — International Journal of Peptide and Protein Research (1978)
Hallazgo Clave: Various short synthetic GH fragments showed biological activity in bioassays, establishing that small regions of GH retain functional properties.
Potencia tu Protocolo de Investigación
4 SinergiasLa investigación sugiere combinar Frag 17-23 con estos péptidos para mecanismos complementarios.
Comparing Frag 17-23 with Fragment 176-191 provides structure-activity insights into different GH regions.
Multi-domain GH research — understanding how different regions of the GH molecule contribute to different biological effects.
CJC/Ipa provides full GH axis stimulation as a reference standard while Frag 17-23 probes a specific GH domain.
Reference GH axis activation plus fragment research for mechanistic understanding.
BPC-157's GH receptor upregulation may enhance the tissue-level effects of Frag 17-23's GH domain activity.
Enhanced fragment activity through receptor upregulation — useful for research into dose-response relationships.
Full-length HGH serves as the reference standard for comparing Frag 17-23's activity to the complete molecule.
Complete GH activity reference plus isolated fragment for structure-activity dissection.
Especificaciones
Precios
| Tamaño | Por Vial | Paquete de 10 |
|---|---|---|
10mg | $70.00 | $595.00 |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Not FDA-approved — research use only
Frag 17-23 is a research peptide with limited published data. No clinical trials have been conducted. All information is for research and educational purposes.
Limited characterization
Frag 17-23 is less well-studied than Fragment 176-191 or other established GH peptides. Biological activity, safety profile, and dosing are not established in humans.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
HGH
Estudiado para la restauración de vías de recuperación relacionadas con la edad
Up to 37% OffHGH Fragment 176-191
Estudiado para lipólisis dirigida sin efectos de crecimiento
CJC1295 with DAC
Estudiado para soporte sostenido de GH con dosificación semanal
Up to 40% OffCJC 1295 (without DAC)
Estudiado para la liberación pulsátil de GH imitando el ritmo natural